CN110054677A - 用于治疗退变性病症的ledgf肽及其制剂 - Google Patents

用于治疗退变性病症的ledgf肽及其制剂 Download PDF

Info

Publication number
CN110054677A
CN110054677A CN201811628163.9A CN201811628163A CN110054677A CN 110054677 A CN110054677 A CN 110054677A CN 201811628163 A CN201811628163 A CN 201811628163A CN 110054677 A CN110054677 A CN 110054677A
Authority
CN
China
Prior art keywords
ledgf
composition
peptide
disease
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811628163.9A
Other languages
English (en)
Chinese (zh)
Inventor
乌达伊·B·康佩拉
林库·拜德
阿伦·K·乌帕德亚伊
萨拉·扬德拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of CN110054677A publication Critical patent/CN110054677A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201811628163.9A 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂 Pending CN110054677A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
US61/649,847 2012-05-21
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
USPCT/US2012/065620 2012-11-16
CN201380038504.6A CN104470534A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380038504.6A Division CN104470534A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Publications (1)

Publication Number Publication Date
CN110054677A true CN110054677A (zh) 2019-07-26

Family

ID=49624295

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811628163.9A Pending CN110054677A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂
CN201380038504.6A Pending CN104470534A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380038504.6A Pending CN104470534A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Country Status (12)

Country Link
US (2) US9526760B2 (enExample)
EP (1) EP2852399B1 (enExample)
JP (2) JP6632376B2 (enExample)
CN (2) CN110054677A (enExample)
AU (1) AU2013266468B2 (enExample)
BR (1) BR112014028951A8 (enExample)
CA (1) CA2873771A1 (enExample)
DK (1) DK2852399T3 (enExample)
ES (1) ES2791251T3 (enExample)
IN (1) IN2014MN02461A (enExample)
RU (1) RU2617964C2 (enExample)
WO (1) WO2013177198A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014028951A8 (pt) * 2012-05-21 2021-09-14 Univ Colorado Regents Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
US11793758B2 (en) 2018-06-22 2023-10-24 Bioralix B.V. Formulations of biological polymers for oral administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074961A1 (en) * 2004-05-06 2010-03-25 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
CN102123729A (zh) * 2008-06-26 2011-07-13 奥菲泽米有限公司 Hsp70作为酶促活性调节物的应用
US20120028889A1 (en) * 2002-09-26 2012-02-02 K.U. Leuven Research & Development Integrase cofactor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1562627A4 (en) 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
WO2004048938A2 (en) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
US8999633B2 (en) * 2004-05-28 2015-04-07 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
WO2007078922A2 (en) 2005-12-30 2007-07-12 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008053478A2 (en) * 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008103265A2 (en) * 2007-02-16 2008-08-28 The Brigham And Women's Hospital, Inc. Methods of using ledgf/p75
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
ES2574790T3 (es) * 2011-07-01 2016-06-22 Inova Diagnostics, Inc. Procedimiento para aumentar la especificidad de pruebas de diagnóstico para enfermedades autoinmunitarias
BR112014028951A8 (pt) * 2012-05-21 2021-09-14 Univ Colorado Regents Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028889A1 (en) * 2002-09-26 2012-02-02 K.U. Leuven Research & Development Integrase cofactor
US20100074961A1 (en) * 2004-05-06 2010-03-25 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
CN102123729A (zh) * 2008-06-26 2011-07-13 奥菲泽米有限公司 Hsp70作为酶促活性调节物的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RINKU BAID等: "LEDGF1-326 Decreases P23H and Wild Type Rhodopsin Aggregates and P23H Rhodopsin Mediated Cell Damage in Human Retinal Pigment Epithelial Cells", 《PLOS ONE》 *

Also Published As

Publication number Publication date
RU2014151603A (ru) 2016-07-10
BR112014028951A2 (pt) 2017-07-25
EP2852399A1 (en) 2015-04-01
EP2852399B1 (en) 2020-02-19
AU2013266468B2 (en) 2017-11-09
JP2018172386A (ja) 2018-11-08
ES2791251T3 (es) 2020-11-03
US9526760B2 (en) 2016-12-27
IN2014MN02461A (enExample) 2015-07-10
WO2013177198A1 (en) 2013-11-28
US20170129929A1 (en) 2017-05-11
DK2852399T3 (da) 2020-05-04
AU2013266468A1 (en) 2014-12-18
EP2852399A4 (en) 2016-03-23
US10221226B2 (en) 2019-03-05
CA2873771A1 (en) 2013-11-28
BR112014028951A8 (pt) 2021-09-14
JP2015519343A (ja) 2015-07-09
US20150147404A1 (en) 2015-05-28
JP6632376B2 (ja) 2020-01-22
RU2617964C2 (ru) 2017-04-28
CN104470534A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
JP6585720B2 (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
EP2968471B1 (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US9102763B2 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
EP3973977A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN114796451B (zh) 使用多肽治疗白内障的方法
US10221226B2 (en) LEDGF peptides and formulations thereof for treatment of degenerative disorders
JP2014501748A (ja) 涙代用物
JPWO2016104690A1 (ja) 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
EP2083841B1 (en) SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE
Zhang et al. Amino acid sequence determines the adjuvant potency of ad-tetra-peptide hydrogel
US9701713B2 (en) Compositions and methods for introduction of macromolecules into cells
CN114401737A (zh) 用于治疗或预防眼科病症的药剂
US20120165268A1 (en) P53 fusion proteins and methods of making and using thereof
TW202227137A (zh) 藥物和野生型穿膜肽衍生物的組合物
CN103159851B (zh) 预防和抑制炎症的小分子多肽及其应用
CN115997021B (zh) 具有降低的免疫原性的trail组合物
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
WO2024115767A1 (en) Nomacopan-pas fusion proteins
WO2025077862A1 (zh) 一种NGF-Fc融合蛋白制剂及其应用
HK40073385B (en) Methods for treating cataracts using polypeptides
TW202415387A (zh) 用於治療眼科疾患之持續釋放二氧化矽水凝膠複合物及其使用方法
WO2021120937A1 (zh) 转甲状腺素蛋白进入眼内以及在制备滴剂中的应用
HK40087448A (en) Composition of drug and wild-type cell-penetrating peptide derivative
HK40072504A (en) Agent for use in treatment or prevention of ophthalmic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190726